Published in Cancer Weekly, August 16th, 2011
Hiebert and his colleagues at Vanderbilt University have obtained drugs that inhibit HDAC3-another epigenetic control element leading to abnormal gene programs, and ultimately cancer. Scientists believe that by eliminating BCL6, they can turn the genes back on and kill the cancer cells. If the researchers can inhibit HDAC3, they hope to knock out B-cell lymphoma completely.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.